Orsini and KalVista's Partnership to Enhance HAE Treatment
Orsini Selected as Specialty Pharmacy Partner for EKTERLY
EKTERLY is an FDA-approved oral therapy designed to treat hereditary angioedema (HAE) during acute attacks.
Orsini, known for its specialty pharmacy solutions in rare diseases, has been chosen by KalVista Pharmaceuticals as the partner for EKTERLY (sebiapterin), aimed at serving patients over 12 years old impacted by HAE. This partnership is set to enhance the delivery of healthcare solutions to those in need.
Hereditary angioedema is a rare, inherited condition characterized by severe swelling that can occur in various body parts including limbs, facial areas, digestive system, and even the airway. This condition arises from inadequate functioning or low levels of a critical protein called C1 inhibitor. Attacks can happen with or without evident triggers such as minor trauma or stress. EKTERLY is administered promptly at the start of an HAE attack, aiming to alleviate symptoms swiftly while reducing the intensity and length of the episode. This therapy marks the tenth addition of HAE treatment in Orsini’s extensive portfolio.
“For over 14 years, Orsini has operated at the forefront of HAE care, and our commitment to providing exceptional support to patients remains steadfast,” said Darin DeCarlo, Orsini's Chief Commercial Officer. “We strive to ensure every patient gets the help they require, and we are excited to introduce EKTERLY as another solution for the HAE community.”
Understanding EKTERLY and its Importance
EKTERLY plays a critical role in promptly managing HAE attacks, allowing patients to regain a sense of normalcy during acute episodes. This therapy is particularly significant for patients who may experience frequent and unpredictable attacks, which can considerably disrupt their daily activities and overall quality of life.
The addition of EKTERLY to Orsini's offerings demonstrates the company’s dedication to expanding its range of advanced therapies that address the unique challenges faced by those with rare conditions. Orsini's thoughtful approach to care ensures patients receive the support needed throughout their treatment journey.
Comprehensive Solutions at Orsini
Orsini stands out as a leading provider of specialized care for patients with rare diseases and gene therapies since its inception in 1987. The organization collaborates with biopharma innovators, healthcare providers, and payors, playing an essential role in facilitating access to groundbreaking treatments. The combination of pharmacy distribution, patient services, clinical management, and home infusion services makes Orsini a one-stop solution for rare disease therapies.
Recognizing the importance of personalized care, Orsini employs highly trained therapy care teams who provide individualized attention and support to patients. The firm’s motto, “No Patient is Left Behind™,” reflects its commitment to ensuring that every individual receives the attention and care they deserve.
Orsini's Accreditations and Recognition
Orsini has earned several notable accreditations, including recognitions from the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP. These accolades underline Orsini's excellence in delivering specialized care in the realm of rare diseases and orphan drugs. The URAC designation as a Rare Disease Pharmacy Center of Excellence further solidifies its reputation, alongside ACHC's distinction in Rare Diseases and Orphan Drugs.
Conclusion: The Future of HAE Care
With EKTERLY as part of its therapies, Orsini is poised to transform the landscape of care for patients battling hereditary angioedema. The collaboration with KalVista promises to enhance access to significant treatments, ultimately promoting better health outcomes for patients managing this complex condition. As Orsini continues to expand its services, its unwavering commitment to innovative solutions and compassionate care ensures that patients can face their daily challenges with renewed hope and support.
Frequently Asked Questions
What is EKTERLY used for?
EKTERLY is an FDA-approved therapy for the rapid treatment of hereditary angioedema (HAE) attacks in both adults and children aged 12 and older.
Who partners with Orsini for EKTERLY distribution?
KalVista Pharmaceuticals has selected Orsini as the specialty pharmacy partner for EKTERLY, enhancing patient access to the therapy.
What conditions does Orsini focus on?
Orsini specializes in rare diseases and gene therapies, working to provide comprehensive care options for patients dealing with these challenging conditions.
How does EKTERLY help patients with HAE?
EKTERLY helps patients by providing rapid relief from HAE attack symptoms, potentially reducing their severity and duration, thus improving quality of life.
What is Orsini's commitment to patient care?
Orsini’s mission is encapsulated in its motto: “No Patient is Left Behind™,” emphasizing personalized attention and support for all patients during their treatment journey.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
